N 30

Subscribe to Selected New Research on N 30

2808 relevant articles (38 outcomes, 307 trials/studies) found for this Bio-Agent

Description: derivative of spergualin

Also Known As:

10-(N-(4-(4-guanidinophenyl)butanoyl)-L-seryl)-1,5,10-triazadecane; N-30

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Amidines: 8

Guanidines: 11

N 30: 2808

Experts

1.	Fogagnolo, Paolo: 1 article (12/2005)
2.	Rossetti, Luca: 1 article (12/2005)
3.	Orzalesi, Nicola: 1 article (12/2005)
4.	Mazzolani, Fabio: 1 article (12/2005)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 01/01/1989 - "At necropsy, the average volume of pulmonary metastases in the HFCO animals (n = 30) was significantly greater than in the other four groups" 08/01/2007 - "Those patients with BC and bone metastasis who had undergone whole-body bone scintigraphy and serum TRACP5b activity determination before any therapeutic intervention were designated the pretreated group (n=30)" 05/01/2007 - "To identify a predictive gene expression signature, the different gene expressions between the two groups with and without metastasis in the learning case (n = 30) were analyzed, and the 85 genes expressed differentially were selected" 05/01/2006 - "Thirty-three percent (n=30) of the samples expressed KAI-1 (16 biopsies, 9 resections, and 5 metastasis)" 08/01/2003 - "Preoperative chemoradiotherapy for stage I to III patients significantly impaired NK cell activity (n = 39), and the metastasis-positive ratio significantly increased among patients with stage II or stage III diseases (n = 30)" Get all the results and reference details, order at left...
2.	Major Depressive Disorder (Major Depressive Disorders) 04/01/2008 - "Three groups of subjects were recruited including one group (n = 31) of patients with major depressive disorder with current depression, the second group (n = 30) with major depressed disorder with remission, and the third group (n = 31) of healthy controls" 01/01/2007 - "This cross-sectional study was conducted in public and private clinics from April 2001 to June 2003.Results: Sixty percent of children (N = 30) whose mothers were recently diagnosed with type 2 diabetes had CDRS-R scores consistent with likely or very likely having major depressive disorders" 09/01/2004 - "We report the acute response and outcome in 1-year follow-up of 51 elderly depressive inpatients with major depressive disorder treated with electroconvulsive therapy (ECT) (n = 30) and/or antidepressant therapy (n = 21)" 07/01/1990 - "Major depressive disorder (MDD) patients (n = 66) treated with electroconvulsive therapy were stratified by the presence (n = 30) or absence (n = 36) of delusional symptoms (by Research Diagnostic Criteria) to compare their response to treatment" 03/01/2002 - "At the main experimental session, we tested newly admitted patients with a DSM diagnosis of schizophrenia during remission (N=30), patients with major depressive disorder (MD) (N=18), and healthy controls (N=20)" Get all the results and reference details, order at left...
3.	Ventricular Tachycardia 01/01/1993 - "In group II (n = 30), with clinical ventricular tachycardia, inducibility was in 22 patients using the standard test, and in 23 patients using the new test" 11/01/2000 - "Patients with ventricular tachycardia (VT) inducible during electrophysiological testing (n = 47, mean age 63 +/- 13 years, 83% men), and healthy controls (n = 30, mean age 44 +/- 16 years, 60% men) were subjected to transthoracic external subthreshold stimulation between surface precordial and left subscapular patch electrodes" 12/01/1990 - "In patients with myocardial infarction (n = 41), the value of maximum was significantly greater with ventricular tachycardia (n = 11) than without ventricular tachycardia (n = 30) (0.240 +/- 0.076 vs. 0.130 +/- 0.043 mV.msec; p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)" 02/01/1995 - "We prospectively studied EP characteristics in 159 trials in 62 patients with ventricular tachycardia or ventricular fibrillation during antiarrhythmic therapy and compared EP measures between successful (n = 30) and failed trials (n = 129)" 04/01/1988 - "Twenty-seven patients (15 men, 12 women; mean age 48.9 years) suffering from ventricular tachycardia (VT) (n = 30) were studied by radionuclide angiocardiography with Fourier phase analysis, both in sinus rhythm and during tachycardia" Get all the results and reference details, order at left...
4.	Dyskinesias (Dyskinesia) 04/13/2007 - "The Xhosa schizophrenia patient group with abnormal involuntary movements (n=54) and a subgroup with tardive dyskinesia (n=30) was found to significantly differ in Ala-9Val genotype frequency (P=0.008 and P=0.011 respectively) compared to the Xhosa schizophrenia patient group without abnormal involuntary movements (n=204)" 01/01/2006 - "Using benzodiazepines as an adjunctive treatment did not result in any clear changes for a series of tardive dyskinesia medium-term outcomes (n=30, 2 RCTs, RR not improved to clinically important extent 1.08 CI 0.57 to 2.05)" 01/01/2003 - "Using benzodiazepines as adjunctive treatment did not result in any clear changes for a series of tardive dyskinesia medium term outcomes (RR not improved to a clinically important extent 1.08 CI 0.57 to 2.05, n=30, 2 RCTs; RR not improved at all 1.19 CI 0.3 to 5.3, n=30, 2 RCTs; RR deterioration 1.85 CI 0.3 to 10.1, n=30, 2 RCTs)" 01/01/2008 - "In a single small study valproate significantly reduced tardive dyskinesia (n=30, WMD -3.3, CI -4.9 to -1.7)" 06/01/1998 - "RESULTS: A total of 127 published reports of SSRI-induced movement disorders were identified involving akathisia (n = 30), dystonia (19), dyskinesia (12), tardive dyskinesia (6), parkinsonism (25), and 15 cases of mixed disorders" Get all the results and reference details, order at left...
5.	Deglutition Disorders (Dysphagia) 06/01/2001 - "RESULTS: One week after stenting the dysphagia score improved significantly in both the uncovered (n = 32, 3 +/- 0.1 to 1 +/- 0.1 [means +/- SEMs], p < 0.001) and covered (n = 30, 3 +/- 0.1 to 1 +/- 0.2 [means +/- SEMs], p < 0.001) stents" 11/01/1997 - "Ambulatory pH monitoring was performed preoperatively in 40 patients with achalasia (18 untreated patients and 22 patients after pneumatic dilatation), 27 (68%) of whom complained of heartburn in addition to dysphagia (group A), and postoperatively in 18 of 51 patients who underwent a thoracoscopic (n=30) or laparoscopic (n=21) Heller myotomy (group B)" 10/01/2004 - "RESULTS: Seventy-four episodes of stent-related recurrent dysphagia occurred in 63 patients (29 %), mainly due to tumor overgrowth (n = 30; median 129 days), stent migration (n = 26; median 92 days) and food bolus obstruction (n = 16; median 80 days)" 02/01/2006 - "Patients with dysphagia (n = 30) showed the largest number of obstructive apneic episodes (OAIs) in the acute phase (AHI, 40 episodes; OAI, 30.4 episodes), with a significant reduction in this type of apnea during the stable phase of stroke (AHI, 24.7 episodes; OAI, 17.7 episodes), coinciding with the recovery of pharyngeal muscle function" 09/01/2005 - "Patients with (n = 14) or without (n = 30) GERD were comparable with respect to sex, age, body mass index, cigarette and alcohol consumption, diameter of the esophageal lumen at the level of the ring, resting lower esophageal sphincter pressure, duration of dysphagia, need for taking antacids during the follow-up period, and duration of follow-up" Get all the results and reference details, order at left...
1026 Diseases and 2808 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	mofezolac (N 22)
2.	Antigens
3.	Benzodiazepines
4.	Insulin (Novolin)
5.	Digoxin (Digitek)
6.	Amiodarone (Amiodarona)
7.	Theophylline (Theon)
8.	Diazepam (Valium)
9.	Diamond
10.	deferasirox
836 Drugs and Important Bio-Agents and 1021 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Lasers (Laser)
3.	Sutures (Suture)
4.	Stents
5.	Continuous Positive Airway Pressure
139 Therapies and Procedures and 277 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>